31 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26288689	37	Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT).	Glaxosmithkline
25415648	63	Identification of potent and selective hydantoin inhibitors of aggrecanase-1 and aggrecanase-2 that are efficacious in both chemical and surgical models of osteoarthritis.	Eli Lilly
24316668	34	Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping.	Asahi Kasei Pharma
24044937	59	Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.	University Of Lille
23453070	42	A series of thiazole derivatives bearing thiazolidin-4-one as non-competitive ADAMTS-5 (aggrecanase-2) inhibitors.	Asahi Kasei Pharma
23376997	53	Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.	Universit£
22891645	83	Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).	Glaxosmithkline
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
21982494	75	Continued exploration of biphenylsulfonamide scaffold as a platform for aggrecanase-1 inhibition.	Pfizer
21733683	8	Structure-activity study on a series ofa-glutamic acid scaffold based compounds as new ADAMTS inhibitors.	Chinese Academy Of Sciences
21536437	219	Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.	Astrazeneca
21417219	179	Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.	Central Pharmaceutical Research Institute
21300546	129	The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.	Astrazeneca
20846863	23	New non-hydroxamic ADAMTS-5 inhibitors based on the 1,2,4-triazole-3-thiol scaffold.	University Of Lille
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19625186	59	3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.	Wyeth Research
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19329309	49	Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.	Wyeth Research
18974001	72	N-((8-hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2).	Wyeth Research
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University Of Athens
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
17210252	22	5-((1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5.	Wyeth Research
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16153831	87	Synthesis and SAR of highly selective MMP-13 inhibitors.	Wyeth Research
15324896	71	3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.	Pfizer